Fibrinorel 1gm Injection

Fibrinorel 1gm Injection contains the active component human fibrinogen. It is used to treat bleeding episodes in patients with congenital fibrinogen deficiency. These deficiencies may result from genetic mutations or liver disease. It serves as an adjunct to haemostasis (blood clotting) in adults undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical. It is also used to arrest bleeding and prevent further blood loss in cases of massive haemorrhage. It may be given to women at risk of premature delivery. It is used in patients with acquired fibrinogen deficiency, which may be caused by liver disease, disseminated intravascular coagulation (DIC), afibrinogenemia, hypofibrinogenemia, or other conditions that damage the liver or interfere with its production. Fibrinorel 1gm Injection should not be given to patients who have had an allergic reaction to this medication or other blood products previously. It should not be administered to people who are actively bleeding, as it can increase the risk of blood clot formation. In patients with a history of thrombosis, this medication should not be given without careful consideration. Special considerations are necessary when administering this medication to paediatric and geriatric patients, including dosage adjustments based on age and weight and close monitoring.

Fibrinogen replacement therapy for bleeding disorders Coagulation management in liver diseases Disseminated intravascular coagulation (DIC) Afibrinogenmia Hypofibrinogenemia

Fibrinorel 1gm Injection molecules are converted into fibrin by the enzyme thrombin. Fibrin strands form a meshwork, trapping blood cells and creating a stable blood clot at the site of injury or bleeding. This clot helps to staunch bleeding and promote wound healing. The missing Fibrinorel 1gm Injection enhances the body's ability to form these essential blood clots, preventing excessive bleeding in individuals with Fibrinorel 1gm Injection deficiency disorders.

Fibrinorel 1gm Injection can be administered through several routes, including intravenous (IV), intramuscular (IM), and, in some cases, intraarterial (IA). The healthcare provider determines the choice of administration route based on the patient's needs and the urgency of treatment.

Fibrinorel 1gm Injection causes some side effects like all medications, although not everyone will experience them. Serious Allergic Reactions Transfusion-related acute lung injury (TRALI) Transfusion-associated circulatory overload (TACO) Transfusion-transmitted infections Thrombosis Fluid overload Common Fever Chills Flushing Nausea Headache Mild allergic reactions (itching, hives)

It is essential to assess patients for allergies, potential allergic reactions, and underlying medical conditions like cardiovascular, liver, or kidney diseases, as these factors can impact Fibrinorel 1gm Injection. Medication interactions, especially with anticoagulants or antiplatelet drugs, must be considered, and dosages adjusted accordingly. Thrombocytopenia, kidney dysfunction, and multiple transfusions can affect treatment response and require close monitoring. Patients receiving it from human plasma should be informed of the minimal risk of viral transmission.